Pregnancy in antiphospholipid syndrome : what should a rheumatologist know?
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com..
This review focuses on the management of reproductive issues in women who have antiphospholipid syndrome (APS) or are carriers of antiphospholipid antibodies (aPL). The importance of aPL detection during preconception counselling relies on their pathogenic potential for placental insufficiency and related obstetric complications. The risk of adverse pregnancy outcomes can be minimized by individualized risk stratification and tailored treatment aimed at preventing placental insufficiency. Combination therapy of low-dose acetylsalicylic acid and heparin is the mainstay of prophylaxis during pregnancy; immunomodulation, especially with hydroxychloroquine, should be considered in refractory cases. Supplementary ultrasound surveillance is useful to detect fetal growth restriction and correctly tailor the time of delivery. The individual aPL profile must be considered in the stratification of thrombotic risk, such as during assisted reproduction techniques requiring hormonal ovarian stimulation or during the follow-up after pregnancy in order to prevent the first vascular event.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 63(2024), SI vom: 06. Feb., Seite SI86-SI95 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andreoli, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 08.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/kead537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368099717 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368099717 | ||
| 003 | DE-627 | ||
| 005 | 20240208232114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kead537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1284.xml |
| 035 | |a (DE-627)NLM368099717 | ||
| 035 | |a (NLM)38320595 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pregnancy in antiphospholipid syndrome |b what should a rheumatologist know? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a This review focuses on the management of reproductive issues in women who have antiphospholipid syndrome (APS) or are carriers of antiphospholipid antibodies (aPL). The importance of aPL detection during preconception counselling relies on their pathogenic potential for placental insufficiency and related obstetric complications. The risk of adverse pregnancy outcomes can be minimized by individualized risk stratification and tailored treatment aimed at preventing placental insufficiency. Combination therapy of low-dose acetylsalicylic acid and heparin is the mainstay of prophylaxis during pregnancy; immunomodulation, especially with hydroxychloroquine, should be considered in refractory cases. Supplementary ultrasound surveillance is useful to detect fetal growth restriction and correctly tailor the time of delivery. The individual aPL profile must be considered in the stratification of thrombotic risk, such as during assisted reproduction techniques requiring hormonal ovarian stimulation or during the follow-up after pregnancy in order to prevent the first vascular event | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antiphospholipid antibodies | |
| 650 | 4 | |a antiphospholipid syndrome | |
| 650 | 4 | |a assisted reproduction technologies | |
| 650 | 4 | |a counselling | |
| 650 | 4 | |a heparin | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a low-dose acetylsalicylic acid | |
| 650 | 4 | |a placental insufficiency | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a thrombosis | |
| 700 | 1 | |a Regola, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Caproli, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Crisafulli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Fredi, Micaela |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzaroni, Maria-Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Nalli, Cecilia |e verfasserin |4 aut | |
| 700 | 1 | |a Piantoni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Zatti, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 63(2024), SI vom: 06. Feb., Seite SI86-SI95 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:SI |g day:06 |g month:02 |g pages:SI86-SI95 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kead537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e SI |b 06 |c 02 |h SI86-SI95 | ||